Jacobson Center for Clinical & Translational Research

Main Menu

/research/

Additional Information

 

Contact Us

Parkinson's Disease Research Studies

Study Title:   An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes, Cynapsus)  (Identifier NCT02542696)

Study Purpose:  A 24-week, prospective, multi-center, open-label, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to evaluate the long-term safety, tolerability and efficacy of APL-130277.

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  Stephanie Wilson, RN, for more information, please call 419.383.6721


Study Title:   Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID).   (Identifier NCT02202551)

Study Purpose:  This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  Stephanie Wilson, RN, for more information, please call 419.383.6721


Study Title:   A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-off" (Biotie TOZ-CL05) (Identifier NCT02453386)

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  Stephanie Wilson, RN, for more information, please call 419.383.6721


Study Title:  A Clinical Study of Patients with Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy (RESTORE).  (Identifier NCT02586623)

Study Purpose:  The purpose of this study is to evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) deficiency who have been previously stabilized with droxidopa therapy for symptoms of neurogenic orthostatic hypotension (NOH) (dizziness, light-headedness, or feelings that they are about to black out).

Principal Investigator: Lawrence Elmer, MD

Study Coordinator:  Stephanie Wilson, RN, for more information, please call 419.383.6721

Last Updated: 7/26/16